Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption
about
Biomarkers predicting antidepressant treatment response: how can we advance the field?Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transportersAssociation of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humansP-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodentsNanomedicine in the diagnosis and therapy of neurodegenerative disorders.Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.Drug resistance in brain diseases and the role of drug efflux transporters.The ABCB1 transporter gene and antidepressant response.Pharmacogenetics of antidepressant response.Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.Pharmacogenetics of antidepressantsAntidepressant drug discovery in the postgenomic era.The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.Therapeutic implications of the MDR-1 gene.Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report.Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients.Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.Pharmacogenomics and antidepressant drugs.Antidepressant-drug interactions are potentially but rarely clinically significant.The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord.ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.Pharmacogenetics of chronic pain and its treatment.A review on the relation between the brain-serum concentration ratio of drugs and the influence of P-glycoprotein.Transporter-mediated uptake into cellular compartments.The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient.Mechanisms of antidepressant resistanceDrug transporters: gatekeepers controlling access of xenobiotics to the cellular interior.Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.An update on the ability of St. John's wort to affect the metabolism of other drugs.Psychotropic drug-drug interactions involving P-glycoprotein.A revised role for P-glycoprotein in the brain distribution of dexamethasone, cortisol, and corticosterone in wild-type and ABCB1A/B-deficient mice.Proliferation rates and gene expression profiles in human lymphoblastoid cell lines from patients with depression characterized in response to antidepressant drug therapy.The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study.Treatment-resistant depression: are animal models of depression fit for purpose?ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis.ABCB1 genotyping in the treatment of depression.Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability.ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram.
P2860
Q27026147-7437B242-8374-4B44-8440-E049D74644CBQ28363795-21E7AF16-7A2E-4458-B7E4-5745694065EBQ28544844-7F678751-3DC3-4D01-8425-385806289443Q30544869-2D1E830C-69B3-41FC-9DC3-674B41E22E96Q33726019-C4B51E5F-FBCC-4BE4-8A99-0A1FD27A7B7DQ33985133-2483962A-2F04-4F9D-8FF4-F6AEABAB990AQ33988704-B31D27B2-0B10-435F-AD84-F3BC17CE2ADEQ34062379-0BAA2F81-F57E-4EAB-A22D-81281B53BDD7Q34155796-92580E93-9B26-42E1-AC2D-46B77F574ACEQ34303346-3DDB6464-330B-4271-8C9C-501836FBDA8DQ35026088-6A19F0DF-B1FF-422F-91CB-8D68F1CFA154Q35066464-DA81D306-2CF4-4676-BD6E-766435049773Q35236618-4D0F38A8-FF58-447B-919E-24DF7863FF81Q35708089-87D4542A-AB40-4CB2-BF5D-5B7A057D5E02Q35925779-324013FA-C01C-4714-8F2D-36B68CD604A7Q35965584-1D900492-6940-44F3-92D8-13D5B2886F72Q36036389-8AFE42F6-66A7-4DBE-B5AF-8B29EC8494A4Q36325439-8F7F998B-E836-4D05-B653-084A584DBAC4Q36341660-96252DD7-AF96-4C49-BC96-644E3CDCCC1CQ36438205-C344FD21-918F-4482-9C46-587A848EC466Q36538987-D8BA61D4-26F5-4F73-9338-B32F9E3259EBQ36590671-03C722D2-2AB8-475C-A267-6F479E078997Q36591193-DE711328-E4E1-460F-8F9E-B3705EDF7BCFQ36900075-3BF5DD39-6479-480F-942B-BCAE14BF856FQ36914175-F0B34E39-3A1B-4149-A2CA-F348B6D55EF0Q36985076-4D3F2A46-7203-4F7C-9657-6E458C74AFABQ37024001-A6210B86-DBE4-429E-B568-7F577E4D8C44Q37334088-6DBBF6EB-E099-4D89-B26D-CD79EFF5D592Q37514340-575B0CA4-CDAC-44A1-A348-8F881BA0AE51Q37989490-AB44E425-7CDD-4C22-A5B5-D95F8004BA96Q38011191-F54B4FF2-8F32-4DB3-846A-42AB2DFF90AFQ38047816-CF6FC1F1-1B08-4260-9CF0-01372CB981EBQ38290046-4D75C8C1-9C28-432D-82E0-82A6BF4EB276Q38440275-D6B805B4-26F0-4443-AC9A-A2B839D19C8BQ38453405-853DD138-5670-4899-AAB2-BEDD2F6061DAQ38569708-11769980-EC7B-44F5-BA42-097D8BB6DDBBQ39021015-4FC01BD4-AA92-4362-8104-0903D1EA4F7EQ39029387-579A7405-1481-4C5C-9CD7-892BA47A9F34Q39113007-47C891E1-D869-465B-A2C5-72B093E60453Q39447754-84DCE133-4079-47EC-A75C-600CEAE61D20
P2860
Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Penetration of amitriptyline, ...... P-glycoprotein gene disruption
@ast
Penetration of amitriptyline, ...... P-glycoprotein gene disruption
@en
Penetration of amitriptyline, ...... P-glycoprotein gene disruption
@nl
type
label
Penetration of amitriptyline, ...... P-glycoprotein gene disruption
@ast
Penetration of amitriptyline, ...... P-glycoprotein gene disruption
@en
Penetration of amitriptyline, ...... P-glycoprotein gene disruption
@nl
prefLabel
Penetration of amitriptyline, ...... P-glycoprotein gene disruption
@ast
Penetration of amitriptyline, ...... P-glycoprotein gene disruption
@en
Penetration of amitriptyline, ...... P-glycoprotein gene disruption
@nl
P2093
P1476
Penetration of amitriptyline, ...... P-glycoprotein gene disruption
@en
P2093
P356
10.1016/S0893-133X(99)00095-0
P407
P577
2000-04-01T00:00:00Z
P5875
P6179
1007334032